Research Conclusions
1. The study of the effect of MYODM on movement capacity, measured through the indirect muscles associated with flight, allows tripling the functionality of DM1 model flies, achieving recovery of between 60-70% of the flight capacity of healthy control flies.
2. The study of the effect of MYODM on muscle area achieves approximately 40% recovery of the muscle area of the indirect flight muscles compared to diseased flies, while reaching almost 85% of the muscle area of healthy flies. In other words, MYODM significantly reduces muscle atrophy in the DM1 model.
3. The study of the effect of MYODM on cardiac dysfunction in the dystrophic fly animal model confirms that the product is safe in vivo and that supplementing the diet of these diseased individuals is capable of significantly improving key parameters of the dystrophic heart, such as heart rate and FS fraction.
4. MYODM enables a 96% increase in lifespan and a 65% increase in average survival of dystrophic flies compared to healthy flies.
5. Feeding DM1 model flies with MYODM reduces Redox levels (a measure of ROS) by approximately 30% compared to diseased flies fed exclusively with the standard nutritive medium.
6. Autophagy (the catabolism of cellular components to obtain energy and eliminate toxic proteins and damaged organelles) is activated in DM1. Feeding DM1 model flies with MYODM allows a reduction in autophagy levels by more than 50%.
Clinical Study Conclusions
The data obtained in the pilot interventional clinical study suggest that controlled and dosed administration of caffeine and theobromine over time in MYO-DM could provide significant improvements for:
- Reducing excessive daytime sleepiness
- Increasing the distance covered in the six-minute walk test, at least in adult men with DM1.
- There are indications of other improvements in the health status of patients, which could be demonstrated with studies involving larger cohorts (for example, a trend towards decreased total cholesterol and triglyceride levels).
- This study provides the necessary scientific data to support the transformation of the MYO-DM dietary supplement into a food for special medical purposes for the nutritional management of DM1.
